Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:AVDL NASDAQ:COGT NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.38-3.5%$2.05$1.11▼$5.00$380.58M1.874.36 million shs5.53 million shsAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.54B1.581.39 million shs1.46 million shsCOGTCogent Biosciences$12.66-1.2%$11.83$3.72▼$13.50$1.46B0.351.43 million shs1.78 million shsVERAVera Therapeutics$23.77-3.1%$22.28$18.53▼$51.61$1.57B1.171.88 million shs1.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-3.50%-5.48%-25.00%-34.91%-66.26%AVDLAvadel Pharmaceuticals-2.90%-2.28%+11.84%+60.92%+12.82%COGTCogent Biosciences-1.17%-2.99%+5.68%+78.81%+18.21%VERAVera Therapeutics-3.10%-1.74%+8.19%+4.53%-36.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.38-3.5%$2.05$1.11▼$5.00$380.58M1.874.36 million shs5.53 million shsAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.54B1.581.39 million shs1.46 million shsCOGTCogent Biosciences$12.66-1.2%$11.83$3.72▼$13.50$1.46B0.351.43 million shs1.78 million shsVERAVera Therapeutics$23.77-3.1%$22.28$18.53▼$51.61$1.57B1.171.88 million shs1.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-3.50%-5.48%-25.00%-34.91%-66.26%AVDLAvadel Pharmaceuticals-2.90%-2.28%+11.84%+60.92%+12.82%COGTCogent Biosciences-1.17%-2.99%+5.68%+78.81%+18.21%VERAVera Therapeutics-3.10%-1.74%+8.19%+4.53%-36.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.12560.87% UpsideAVDLAvadel Pharmaceuticals 3.11Buy$20.8635.44% UpsideCOGTCogent Biosciences 2.92Moderate Buy$20.0057.98% UpsideVERAVera Therapeutics 2.90Moderate Buy$63.00165.04% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, VERA, AVDL, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.009/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/13/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $5.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00 ➝ $24.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$29.93M12.27N/AN/A$1.61 per share0.86AVDLAvadel Pharmaceuticals$169.12M8.84N/AN/A$0.77 per share20.00COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A256.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)Latest AUTL, VERA, AVDL, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07AVDLAvadel PharmaceuticalsN/A2.792.38COGTCogent BiosciencesN/A4.194.19VERAVera Therapeutics0.1617.0317.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%AVDLAvadel Pharmaceuticals69.19%COGTCogent BiosciencesN/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%AVDLAvadel Pharmaceuticals5.20%COGTCogent Biosciences7.29%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionableAUTL, VERA, AVDL, and COGT HeadlinesRecent News About These CompaniesWoodline Partners LP Has $24.04 Million Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 12 at 6:41 AM | marketbeat.comVera Therapeutics (VERA) Stock Surges 27% Over Last MonthSeptember 10 at 6:46 PM | finance.yahoo.comSamlyn Capital LLC Sells 683,797 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires New Stake in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Cuts Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Stock Position Lifted by Trexquant Investment LPSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Sells 36,748 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Shares Bought by EFG Asset Management North America Corp.September 6, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Consensus Price Target from BrokeragesSeptember 6, 2025 | americanbankingnews.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comVera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comFirst Light Asset Management LLC Sells 85,367 Shares of Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVestal Point Capital LP Increases Stake in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Grows Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMagnetar Financial LLC Takes Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 4, 2025 | marketbeat.comArmistice Capital LLC Grows Holdings in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comJump Financial LLC Invests $906,000 in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comTri Locum Partners LP Invests $3.61 Million in Vera Therapeutics, Inc. $VERAAugust 30, 2025 | marketbeat.comNuveen LLC Acquires New Position in Vera Therapeutics, Inc. $VERAAugust 30, 2025 | marketbeat.comWalleye Capital LLC Acquires New Stake in Vera Therapeutics, Inc. $VERAAugust 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBJ’s Wholesale Club Pulls Back to Trend: It’s Time for an EntryBy Thomas Hughes | August 25, 2025Should You Join Buffett and Invest in Constellation Brands?By Jordan Chussler | August 22, 2025Monster Is Re-Energized: Can the Stock's Rally Continue?By Leo Miller | August 20, 2025Rocket Lab Strengthens Case for Breakout With New Launch PadBy Ryan Hasson | September 3, 2025Defensive Plays: 3 Consumer Staples Giants Showing StrengthBy Nathan Reiff | September 2, 2025AUTL, VERA, AVDL, and COGT Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.38 -0.05 (-3.50%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Avadel Pharmaceuticals NASDAQ:AVDL$15.40 -0.46 (-2.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.15 -0.25 (-1.62%) As of 09/12/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Cogent Biosciences NASDAQ:COGT$12.66 -0.15 (-1.17%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.70 +0.04 (+0.32%) As of 09/12/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Vera Therapeutics NASDAQ:VERA$23.77 -0.76 (-3.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.54 -0.23 (-0.97%) As of 09/12/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
